|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-4.75/-0.64
|
企业价值
1.49B
|
资产负债 |
每股账面净值
7.28
|
现金流量 |
现金流量率
--
|
损益表 |
收益
17.45M
|
每股收益
0.33
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/18 18:06 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |